# EDGAR Filing Document

**Accession Number:** 0001799448
**File Stem:** 0001193125-26-281134
**Filing Date:** 2026-6
**Character Count:** 9522
**Document Hash:** a25db278afd117b0d0a00a3d53cf79b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-281134.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0001193125-26-281134

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aligos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001799448
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91770
- **FILM NUMBER:** 261116233

**BUSINESS ADDRESS:**
- **STREET 1:** ONE CORPORATE DR., 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (800) 466-6059

**MAIL ADDRESS:**
- **STREET 1:** ONE CORPORATE DR., 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BLATT LAWRENCE
- **CENTRAL INDEX KEY:** 0001242110

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Aligos Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value, $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Lawrence M. Blatt, Ph.D.**<br>One Corporate Dr.<br>2nd Floor<br>South San Francisco CA 94080<br>(800) 466-6059

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/16/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Lawrence M. Blatt** | Name of reporting person<br>**Lawrence M. Blatt** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**316228.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**316228.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**316228.00** | Aggregate amount beneficially owned by each reporting person<br>**316228.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.6%** | Percent of class represented by amount in Row (11)<br>**5.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value, $0.0001 per share

**(b) Name of Issuer:**
Aligos Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
One Corporate Drive, 2nd Floor, South San Francisco, CA, 94080

**Item 4. Purpose of Transaction**

General

The Reporting Person intends to review his investments in the Issuer on a continuing basis. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

The Reporting Person may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. The Reporting Person may also enter into financial instruments or other agreements with institutional or other counterparties that would increase or decrease the Reporting Person's economic exposure with respect to their investment in the Issuer, which instruments or agreements may or may not affect the Reporting Person's beneficial ownership in securities of the Issuer. In addition, the Reporting Person, in his positions as President, Chief Executive Officer and a director of the Issuer, may engage in discussions with management, the Issuer's board of directors (the "Board"), other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Common Stock; security offerings and/or stock repurchases by the Issuer; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board.

To facilitate their consideration of such matters, the Reporting Person may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Person may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Person will likely take some or all of the foregoing steps at preliminary stages in their consideration of various possible courses of action before forming any intention to pursue any particular plan or direction.

Other than as described above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change his purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of June 16, 2026, based upon 5,388,223 shares of voting Common Stock outstanding as of May 1, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2026.

The Reporting Person is the beneficial owner of 316,228 shares of Common Stock, which consist of (i) 3,251 shares of Common Stock held directly by the Reporting Person, (ii) 78,781 shares of Common Stock held by the Lawrence M. Blatt Living Trust dated 8/27/2014, (iii) 4,904 shares of Common Stock held by PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, (iv) 740 shares of Common Stock held by Zachary David Blatt Irrevocable Trust dated 8/24/2014, (v) 740 shares of Common Stock held by Zoe Anne Blatt Irrevocable Trust dated 8/24/2014, (vi) 12,206 shares of common stock held by exercisable warrants and (vii) 215,606 shares of Common Stock underlying stock options held directly by the Reporting Person that are currently exercisable or may be exercised within 60 days of June 16, 2026.

The shares beneficially owned by the Reporting Person consistutes approximately 5.6% of the voting shares outstanding.

**(b)**
Sole power to vote or direct the vote: 316,228

Shared power to vote: 0

Sole power to dispose or direct the disposition of: 316,228

Shared power to dispose or direct the disposition of: 0

**(c)**
During the past 60 days, the Reporting Person has not effected any transactions with respect to the Common Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Lawrence M. Blatt

**Signature:** /s/ Lawrence M. Blatt

**Name/Title:** Lawrence M. Blatt, Ph.D.

**Date:** 06/24/2026